Ubs Group Ag Innate Pharma Sa Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Innate Pharma Sa stock. As of the latest transaction made, Ubs Group Ag holds 5,957 shares of IPHA stock, worth $12,688. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,957
Previous 9,001
33.82%
Holding current value
$12,688
Previous $16,000
37.5%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding IPHA
# of Institutions
11Shares Held
98.7KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY51.2KShares$109,1070.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il26.6KShares$56,6940.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7KShares$24,8370.0% of portfolio
-
Gamma Investing LLC Foster City, CA2.28KShares$4,8580.0% of portfolio
-
Rhumbline Advisers Boston, MA470Shares$1,0010.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $170M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...